{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:40:07Z","timestamp":1749058807199,"version":"3.41.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073708"],"award-info":[{"award-number":["82073708"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejmech.2025.117435","type":"journal-article","created":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T15:09:15Z","timestamp":1740323355000},"page":"117435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The discovery of novel N-heterocyclic-based AKT inhibitors with potential efficacy against prostate cancer"],"prefix":"10.1016","volume":"289","author":[{"given":"Jinxiao","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dezhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihao","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangzhe","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5391-7993","authenticated-orcid":false,"given":"Guisen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117435_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1432-1033.1991.tb16305.x","article-title":"Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families","volume":"201","author":"Coffer","year":"1991","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2025.117435_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116698","article-title":"Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy","volume":"276","author":"Alt\u0131ntop","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117435_bib3","first-page":"2475","article-title":"AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon","volume":"7","author":"Zinda","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117435_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117435_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116906","article-title":"The evolution of small-molecule Akt inhibitors from hit to clinical candidate","volume":"279","author":"Tian","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117435_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejmech.2019.07.017","article-title":"Discovery of pyrazole-thiophene derivatives as highly Potent, orally active Akt inhibitors","volume":"180","author":"Zhan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117435_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/378785a0","article-title":"Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B","volume":"378","author":"Cross","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117435_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127375","article-title":"A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies","volume":"253","author":"Thapa","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2025.117435_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.imlet.2011.02.007","article-title":"Sat-Nav for T cells: role of PI3K isoforms and lipid phosphatases in migration of T lymphocytes","volume":"138","author":"Ward","year":"2011","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ejmech.2025.117435_bib10","first-page":"4268","article-title":"Satb1 promotes Schwann cell viability and migration via activation of PI3K\/AKT pathway","volume":"22","author":"Liu","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.117435_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pharmthera.2016.12.001","article-title":"Maximising the potential of AKT inhibitors as anti-cancer treatments","volume":"172","author":"Brown","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.117435_bib12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","article-title":"Akt in cancer: mediator and more","volume":"59","author":"Revathidevi","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.117435_bib13","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1021\/acs.jmedchem.4c00075","article-title":"Akt inhibitor advancements: from capivasertib approval to covalent-allosteric promises","volume":"67","author":"Pervanidis","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117435_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107019","article-title":"Design, synthesis, and biological evaluation of N-(pyridin-3-yl)pyrimidin-4-amine analogues as novel cyclin-dependent kinase 2 inhibitors for cancer therapy","volume":"143","author":"Zeng","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117435_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114864","article-title":"Rational design, synthesis and biological evaluation of novel 2-(substituted amino)-[1,2,4]triazolo[1,5-a]pyrimidines as novel tubulin polymerization inhibitors","volume":"244","author":"Chen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117435_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113449","article-title":"Discovery of highly potent tubulin polymerization inhibitors: design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines","volume":"220","author":"Huo","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117435_bib17","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1021\/jm8004527","article-title":"Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase","volume":"51","author":"Heerding","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117435_bib18","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1158\/0008-5472.CAN-07-5783","article-title":"Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity","volume":"68","author":"Rhodes","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117435_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2019.05.003","article-title":"Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer","volume":"154","author":"Liu","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117435_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00280-014-2615-5","article-title":"Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma","volume":"75","author":"Tolcher","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117435_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117435_bib22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1535-7163.MCT-05-0005","article-title":"Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo","volume":"4","author":"Luo","year":"2005","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117435_bib23","doi-asserted-by":"crossref","first-page":"8144","DOI":"10.1021\/acs.jmedchem.2c00527","article-title":"Discovery of clinical candidate NTQ1062 as a potent and bioavailable akt inhibitor for the treatment of human tumors","volume":"65","author":"Ma","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117435_bib24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40265-024-01998-6","article-title":"Capivasertib: first approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117435_bib25","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1021\/jm1003842","article-title":"Design of selective, ATP-competitive inhibitors of Akt","volume":"53","author":"Freeman-Cook","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117435_bib26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2017.06.067","article-title":"Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity","volume":"138","author":"Liu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117435_bib27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1039\/C8MD00197A","article-title":"Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant","volume":"9","author":"Zhang","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2025.117435_bib28","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1038\/sj.onc.1210343","article-title":"Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition","volume":"26","author":"Han","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117435_bib29","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2008-02-137737","article-title":"AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines","volume":"113","author":"Levy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117435_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12964-019-0450-3","article-title":"Distinct functions of AKT isoforms in breast cancer: a comprehensive review","volume":"17","author":"Hinz","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.117435_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2017.05.011","article-title":"AGC kinases, mechanisms of regulation and innovative drug development","volume":"48","author":"Leroux","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.117435_bib32","doi-asserted-by":"crossref","first-page":"18823","DOI":"10.1002\/anie.201909857","article-title":"Covalent-allosteric inhibitors to achieve akt isoform-selectivity","volume":"58","author":"Quambusch","year":"2019","journal-title":"Angew Chem. Int. Ed. Engl."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:24:00Z","timestamp":1749057840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425002004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"alternative-id":["S0223523425002004"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117435","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The discovery of novel N-heterocyclic-based AKT inhibitors with potential efficacy against prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117435"}}